CytomX Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of CytomX Therapeutics (CTMX) with an Overweight rating and $6 price target CytomX may have a real contender on its hands with CX-051, a masked epithelial cell adhesion molecule antibody-drug conjugate, and one it can build a franchise around, the analyst tells investors in a research note. Cantor likes the setup, saying that if CX-2051 delivers, CytomX owns a first-in-class space with blockbuster potential in colorectal cancer, and optionality well beyond that.